# Restech

> Restech is a Houston-founded medical device company specializing in upper-airway pH monitoring and minimally invasive digestive-health therapies. Its Dx-pH system serves clinicians investigating suspected laryngopharyngeal reflux; acquisitions added Stretta, Secca and Reflux Band, alongside PepsinCheck commercialization. Restech-branded Dx-pH and several related products are now presented by The Reflux Company, founded in 2025.

- **Founded:** 2003
- **Headquarters:** Houston, United States
- **Founders:** Jeff Schipper (Co-founder; director (public company profile))
- **Products:** Dx-pH Measurement System, Reflux Cloud, Stretta, Secca, PepsinCheck by Peptest
- **Notable:** Developed an upper-airway pH sensor capable of measurements in liquid and aerosolized environments., Expanded from diagnostics into therapy through the 2018 Mederi asset acquisition., Added domestic U.S. fulfillment and laboratory processing for PepsinCheck in 2020.

## Products & services

- **Dx-pH Measurement System** — Clinician-operated upper-airway pH monitoring using a transnasal probe, transmitter and wearable recorder; measures pH in liquid and aerosolized environments.
- **Reflux Cloud** — The current Dx-pH product page describes this reporting platform for mapping recorded events to symptoms; pricing and launch year are not specified.
- **Stretta** — Endoscopic RF therapy for selected GERD patients, acquired in 2018. The Reflux Company announced a planned January 2027 relaunch; clinical society recommendations differ.
- **Secca** — RF therapy targeting the anal sphincter for bowel incontinence, acquired alongside Stretta in 2018; historical offering, with current availability unverified.
- **PepsinCheck by Peptest** — U.S. commercialization of RD Biomed’s saliva-based pepsin test; U.S. shipping and laboratory processing announced in May 2020.
- **Reflux Band** — External nighttime upper esophageal sphincter compression device acquired with Somna Therapeutics assets in June 2020.
- **Clinical training and technical support** — Public product instructions describe on-site and internet-based training for healthcare professionals using Dx-pH.

## Achievements

- Developed an upper-airway pH sensor capable of measurements in liquid and aerosolized environments.
- Expanded from diagnostics into therapy through the 2018 Mederi asset acquisition.
- Added domestic U.S. fulfillment and laboratory processing for PepsinCheck in 2020.
- Added Reflux Band through the 2020 Somna asset acquisition.

## Latest updates

- **2026-06** — The Reflux Company announced Nissha Medical Technologies as manufacturing partner for Stretta and targeted January 2027 for release.
- **2026-04** — The Reflux Company announced a fully subscribed $1 million seed round, expected to close in early Q2, with MAAB Group participation and an Asia commercialization agreement.
- **—** — Thomas Ball founded The Reflux Company, whose current portfolio presents Restech Dx-pH, Stretta, Reflux Band and PepsinCheck by Peptest.

## Links

- Website: http://www.restech.com
- LinkedIn: https://www.linkedin.com/company/restech
- Twitter/X: https://twitter.com/rethink_reflux
- YouTube: https://www.youtube.com/user/Restech1office
- Facebook: https://www.facebook.com/rethinkreflux/

---

Profile page: https://yespress.io/restech
Published by YesPress — https://yespress.io
Last updated: 2026-10-03